Format

Send to

Choose Destination
J Neurosci Rural Pract. 2017 Apr-Jun;8(2):225-227. doi: 10.4103/0976-3147.203820.

Lennox-Gastaut Syndrome: A Prospective Follow-up Study.

Author information

1
Department of Neurology, King George Medical University, Lucknow, Uttar Pradesh, India.

Abstract

OBJECTIVES:

Lennox-Gastaut syndrome is a catastrophic epileptic encephalopathy. In Lennox-Gastaut syndrome, seizures are resistant to pharmacological treatment. In this prospective study, we evaluated the clinical features, neuroimaging, and response to treatment.

MATERIALS AND METHODS:

Forty-three consecutive newly diagnosed patients of Lennox-Gastaut syndrome were enrolled in the study. Baseline clinical assessment included seizure semiology, seizure frequency, electroencephalography, and neuroimaging. Patients were treated with combinations of preferred antiepileptic drugs (sodium valproate [VPA], clobazam [CLB], levetiracetam [LVT], lamotrigine [LMT], and topiramate [TPM]). Patients were followed for 6 months. The outcome was assessed using modified Barthel index.

RESULTS:

Tonic and generalized tonic-clonic forms were the most common seizures types. Features suggestive of hypoxic-ischemic encephalopathy (37.2%) were most frequent neuroimaging abnormality. Neuroimaging was normal in 32.6% of patients. With a combination valproic acid (VPA), CLB, and LVT, in 81.4% of patients, we were able to achieve >50% reduction in seizure frequency. Eleven (25.58%) patients showed an improvement in the baseline disability status.

CONCLUSIONS:

A combination of VPA, CLB, and LVT is an appropriate treatment regimen for patients with Lennox-Gastaut syndrome.

KEYWORDS:

Clobazam; Lennox–Gastaut syndrome; levetiracetam; seizure; valproic acid

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center